On Thursday, Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.

Amphastar is a biopharmaceutical company focusing primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products.

The company reported sales of $186.5 million, up 20% year over year, missing the consensus of $188.81 million.

Also Read: JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability

Primatene MIST exceeded the long-term goal of $100 million in annual sales (around $29 million in the quarter), while BAQSIMI contributed $41.8 million in direct sales during the fourth quarter alone ($126.9 million for the full year).

JP Morgan says the company has seen some setbacks over the past several months, including a competitive approval for glucagon (~15% of Amphastar revenues) and several pipeline delays.

Analyst Ekaterina Knyazkova sees limited downside for the stock as Amphastar shares are now in the low $30s. Primatene MIST and Baqsimi continue growing, with the current valuation reflecting little value for Amphastar’s extensive R&D efforts and pipeline.

JP Morgan maintains the Overweight rating for Amphastar’s stock with a price target of $45.

Price Action: AMPH stock is down 8.35% at $28.86 at the last check Friday.

Read Next:

• Nayax Expands In Brazil With UPPay Acquisition, Taps Into New Payment Points

Photo by Ground Picture on Shutterstock.